We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Champions Oncology (CSBR - Free Report) closed at $10.39, marking a +0.39% move from the previous day. This change outpaced the S&P 500's 0.3% gain on the day. At the same time, the Dow 0%, and the tech-heavy Nasdaq gained 0.92%.
Prior to today's trading, shares of the company had lost 7.48% over the past month. This has lagged the Medical sector's loss of 2.5% and the S&P 500's loss of 4.06% in that time.
CSBR will be looking to display strength as it nears its next earnings release, which is expected to be December 6, 2018. Our most recent consensus estimate is calling for quarterly revenue of $6.35 million, up 22.12% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.17 per share and revenue of $25.31 million, which would represent changes of +440% and +25.06%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CSBR. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CSBR currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, CSBR is holding a Forward P/E ratio of 61.12. This represents a premium compared to its industry's average Forward P/E of 16.91.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Champions Oncology (CSBR - Free Report) closed at $10.39, marking a +0.39% move from the previous day. This change outpaced the S&P 500's 0.3% gain on the day. At the same time, the Dow 0%, and the tech-heavy Nasdaq gained 0.92%.
Prior to today's trading, shares of the company had lost 7.48% over the past month. This has lagged the Medical sector's loss of 2.5% and the S&P 500's loss of 4.06% in that time.
CSBR will be looking to display strength as it nears its next earnings release, which is expected to be December 6, 2018. Our most recent consensus estimate is calling for quarterly revenue of $6.35 million, up 22.12% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.17 per share and revenue of $25.31 million, which would represent changes of +440% and +25.06%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CSBR. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CSBR currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, CSBR is holding a Forward P/E ratio of 61.12. This represents a premium compared to its industry's average Forward P/E of 16.91.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.